LinkedIn Profile

Access THERAVECTYS historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:theravectys 969169 Dec 3rd, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Dec 3rd, 2020 02:58PM Dec 3rd, 2020 02:58PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Dec 2nd, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Dec 2nd, 2020 04:46PM Dec 2nd, 2020 04:46PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Dec 1st, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Dec 1st, 2020 03:17PM Dec 1st, 2020 03:17PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 30th, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 29th, 2020 09:17PM Nov 30th, 2020 04:05PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 28th, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 28th, 2020 04:51PM Nov 28th, 2020 04:51PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 27th, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 27th, 2020 01:17PM Nov 27th, 2020 01:17PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 26th, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 25th, 2020 08:16PM Nov 25th, 2020 08:16PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 24th, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 24th, 2020 03:49PM Nov 24th, 2020 03:49PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 23rd, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 23rd, 2020 05:38PM Nov 23rd, 2020 05:38PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences
private:theravectys 969169 Nov 22nd, 2020 12:00AM THERAVECTYS 2.2K 19.00 Open Biotechnology Nov 22nd, 2020 04:34PM Nov 22nd, 2020 04:34PM THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health. Open Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors Open 3 rue de l'arrivée, , BP 033 Paris Cedex 15 Ile-de-France FR 75749 Pharmaceuticals & Biotechnology Health Care Pharmaceuticals, Biotechnology & Life Sciences

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.